噬菌体抗体库技术在肿瘤抗体药物研究中的进展及应用

目的:综述噬菌体抗体库技术的研究进展,介绍该技术的原理,构建,筛选和应用,为抗肿瘤抗体药物研发提供参考。方法:采用文献综述的方法,筛选近5年来噬菌体抗体库技术试验论文,对噬菌体抗体库技术的原理,构建,筛选和应用进行总结。结果:噬菌体抗体库主要分为免疫抗体库和非免疫抗体库两大类;噬菌体抗体库筛选技术包括亲和筛选、细胞筛选和生物体内筛选三种;噬菌体抗体库技术主要应用于肿瘤标志物的识别和肿瘤诊断,抗肿瘤抗体药物的筛选和制备。结论:噬菌体抗体库技术方便、快速、高效,可以在体外环境下培养,这些特点决定了其在肿瘤标志物的发现和肿瘤抗体药物研发中的广泛应用。目前噬菌体抗体库技术还存在一定缺陷,但技术的不断发展和革新必然使噬菌体抗体库技术成为研制抗体药物的新思路,极大促进了肿瘤抗体药物的研发。     

利用重组系统构建大容量噬菌体抗体库

噬菌体抗体库技术是获得人源抗体的重要方法,此文探讨大容量天然噬菌体抗体库在筛选人源抗体中的实际应用价值。从正常人外周血分离淋巴细胞,通过基因工程方法获得抗体基因并且构建到含有重组位点的载体pDF中获得初级噬菌体抗体库,初级库在重组系统中重组之后获得了容量为9×1010的天然Fab噬菌体抗体库,通过序列测定和重组蛋白筛选来对抗体库的质量进行初步鉴定。对随机挑取的96个克隆测序序列分析表明各种型别比例基本合适;用四种抗原筛选有明显的富集,并且获得了针对其中一种抗原的阳性抗体克隆。     

噬菌体单链抗体文库的构建及筛选

噬菌体抗体是继多克隆抗体、单克隆抗体之后兴起的第3代基因工程抗体.噬菌体抗体库技术是抗体基因文库技术和噬菌体表面展示技术相结合形成的一项新技术与方法,在生物科学领域极具潜力.现主要就近年来该技术在抗体基因扩增、抗体库的构建、筛选方法等方面的进展进行综述.     

噬菌体抗体库技术制备高亲和力人抗体

噬菌体抗体库技术的基本原理是将全套抗体可变区基因组装到丝状噬菌体表达载体内 ,与噬菌体外壳蛋白Ⅲ或Ⅷ基因融合并表达到噬菌体表面 ,以固相化的抗原作配基 ,通过吸附 洗脱 扩增的富集过程 ,筛选到与抗原特异结合的抗体克隆 ,并得到相应的抗体可变区基因。因此噬菌体抗体库技术可以被认为是体内抗体生成过程的模拟 ,首先建立足够多样性的抗体库 ,然后通过免疫亲和筛选即可能得到针对任何抗原的人抗体。该技术省时省力 ,无...     

噬菌体抗体展示技术及其在抗新冠病毒抗体发现中的应用

噬菌体抗体展示技术是第一个也是目前应用最广泛的体外抗体筛选技术,可用于发现治疗各种疾病的全人源抗体。虽然存在不同的抗体发现方法,但噬菌体抗体展示技术已成为发现和优化靶标特异性单克隆抗体不可或缺的工具。研究人员可通过在丝状噬菌体上创建组合抗体库,从而在几周内获得抗原特异性抗体。在当前冠状病毒病(COVID-19)大流行的情况下,对中和抗体的研究激励着研究人员寻找出抗SARS-CoV-2的候选治疗药物。通过对噬菌体抗体库的筛选,目前已有许多不同的SARS-CoV-2中和抗体被发现。因此,本文综述了噬菌体抗体展示技术的原理,抗体库的构建、分类及淘选流程,并对其优点及局限性进行了讨论。此外,还总结了利用该技术发现抗SARS-CoV-2中和抗体的最新进展。旨为今后该技术在抗体发现中的应用提供理论支持。     

抗病毒噬菌体抗体库研究进展

噬菌体抗体库技术是基于噬菌体表面展示技术发展起来的一项基因抗体工程新技术.它将含亿万种基因的抗体可变区基因库转化成展示在噬菌体表面的蛋白库,不仅使对于具备所需属性的单克隆抗体筛选能更方便、快速、高效地在体外进行,还开辟了单克隆抗体人源化的新途径,揭开了人类单克隆抗体生产的历史新篇章.本文综述了近年来针对各种病毒的噬菌体抗体库的构建、筛选方法以及其在各种病毒性疾病研究中的最新进展.     

双峰驼源天然噬菌体纳米抗体展示库的构建及抗GDH纳米抗体筛选

目的:构建噬菌体天然纳米抗体展示库,以期用于筛选不同抗原分子的纳米抗体筛选平台,并用艰难梭菌谷氨酸脱氢酶(GDH)抗原筛选靶向GDH的纳米抗体,对所构建的噬菌体天然纳米抗体展示库进行验证。方法:采用Oligo DT提取双峰骆驼脾脏总RNA进行反转录,通过巢氏PCR获取全套重链可变区基因,将其构建到噬菌粒pCANTAB5E载体,经多次电转化至E. coil TG1构建初级噬菌体抗体库,经辅助噬菌体拯救后构成噬菌体展示库,并对噬菌体展示库的库容及多样性进行分析和鉴定。同时以GDH为靶向抗原对文库进行淘筛,计算淘筛回收率,并对第三轮淘筛后平板的单克隆进行ELISA鉴定。结果:构建的天然噬菌体纳米抗体库的插入率为95%左右,随机挑取的9个克隆氨基酸同源性为66. 17%,经MEGA分析后具有较好的多样性,同时经辅助噬菌体拯救后,得到的噬菌体展示库滴度为4×10~(12)CFU/ml。在三轮淘筛过程中,回收率逐步升高,噬菌体得到了有效的富集,同时对阳性克隆进行测序及分析,最终得到2条抗GDH纳米抗体序列。结论:成功构建了双峰驼源天然噬菌体纳米抗体展示文库且多样性良好,为后续筛选其他的靶向抗原奠定了基础,同时筛选获得两条抗GDH纳米抗体序列,为制备艰难梭菌谷氨酸脱氢酶诊断抗体提供技术支撑。     

噬菌体展示抗体库筛选技术研究进展

噬菌体展示技术已成为制备高亲和力抗体的强有力的工具。而噬菌体抗体库的筛选是在获得高亲和力抗体过程中很关键的一个环节。总结了针对不同复杂程度的抗原所须采用的不同筛选方法,并简单介绍了高通量筛选的优势。     

人源天然ScFv噬菌体抗体库的构建及鉴定

噬菌体抗体库技术是获得治疗性抗体的一条重要途径。以20份健康人外周血为样本,通过提取淋巴细胞、逆转录－PCR（RT PCR）、抗体可变区基因的扩增、重叠PCR获得单链抗体（ScFv）基因,将ScFv克隆入噬粒载体,通过近300次的电转化获得了库容量为1.3×109的全人源天然ScFv噬菌体抗体库。通过随机挑克隆测序和用5种不同抗原筛选对抗体库进行了初步验证。随机测序表明抗体库具有较好的多样性,用5种不同抗原对其进行筛选,均获得了特异性噬菌体抗体的不同富集,表明成功构建了一个多样性良好的人源天然ScFv噬菌体抗体库。     

噬菌体抗体库技术

噬菌体抗体库技术用ＰＣＲ扩增出抗体的全套可变区基因,通过噬菌体表面表达技术,把Ｆａｂ段或单链抗体表达在噬菌体表面,经过“吸附－洗脱－扩增”过程筛选并富集特异性抗体。     

噬菌体表面呈现技术研究进展

噬菌体表面呈现技术是1985年建立的一种将外源基因表达呈现在噬菌体颗粒表面的方法,可用于建立随机多肽文库、抗体文库等。经特定配基的筛选,可获得与其特异结合的配体分子。通过改构,还可将cDNA产物表达于噬菌体颗粒的尾部构建cDNA文库。SIP技术通过将配体和配基分别与基因Ⅲ蛋白的C末端和N末端融合表达,基因Ⅲ的C-末端参与噬菌体颗粒的组装,配基与配体的结合能够重建基因Ⅲ蛋白的功能,才能形成有感染能力的噬菌体,这样就大大提高了筛选效率。     

Going native: Direct high throughput screening of secreted full-length IgG antibodies against cell membrane proteins

Gel microdroplet – fluorescence activated cell sorting (GMD-FACS) is an innovative high throughput screening platform for recombinant protein libraries, and we show here that GMD-FACS can overcome many of the limitations associated with conventional screening methods for antibody libraries. For example, phage and cell surface display benefit from exceptionally high throughput, but generally require high quality, soluble antigen target and necessitate the use of anchored antibody fragments. In contrast, the GMD-FACS assay can screen for soluble, secreted, full-length IgGs at rates of several thousand clones per second, and the technique enables direct screening against membrane protein targets in their native cellular context. In proof-of-concept experiments, rare anti-EGFR antibody clones were efficiently enriched from a 10,000-fold excess of anti-CCR5 clones in just three days. Looking forward, GMD-FACS has the potential to contribute to antibody discovery and engineering for difficult targets, such as ion channels and G protein-coupled receptors.     

The use of recombinant antibodies in proteomics

Recombinant antibodies are becoming increasingly important in the field of proteomics. Recent advances include the development of large phage-antibody libraries that contain high-affinity binders to almost any target protein, and new methods for high-throughput selection of antibody-antigen interactions. Coupled with a range of new screening technologies that use high-density antibody arrays to identify differentially expressed proteins, these antibody libraries can be applied to whole proteome analysis.     

Method for generation of human hyperdiversified antibody fragment library

The selection of antibody fragments from libraries using in vitro screening technologies has proven to be a very good alternative to the classical hybridoma technology, and has overcome the laborious process of antibody humanization. However, the complexity of the library is critical in the probability of being able to directly isolate a high affinity antibody specific to a target. We report a method to make hyperdiversified antibody fragment libraries, based on human immunoglobulin variable genes mimicking the somatic hypermutation process. This mutagenesis technology, MutaGen, was used for the first time on the entire variable domain (frameworks and CDRs) of large repertoires of human variable antibody domains. Our MutaGen process uses low-fidelity human polymerases, known as mutases, suggested to be involved in the somatic hypermutation process of immunoglobulin genes. Depending on the mutases used, we generated complementary mutation patterns with randomly distributed mutations. The libraries were generated with an average of 1.8 mutations per 100 amino acids. The hyperdiversified antibody fragment libraries constructed with our process should enable the selection of antibody fragments specific to virtually any target.     

Recombinant antibody libraries and selection technologies

Active immunization has benefited human health perhaps more than any other biomedical advancement. Today, passive immunization is profoundly changing the practice of medicine by enabling antibody targeting of toxic, self, and other antigens not conducive to active immunization. Recombinant antibody libraries have contributed greatly to this progress and will continue to do so. The ability to construct and display a variety of antibody libraries, including naive, immune, semi-synthetic, and synthetic ones coupled with rapid screening and selection technologies, is in large measure responsible for the thousands of monoclonal antibody therapeutics in development.     

Femtomolar Fab binding affinities to a protein target by alternative CDR residue co-optimization strategies without phage or cell surface display

In therapeutic or diagnostic antibody discovery, affinity maturation is frequently required to optimize binding properties. In some cases, achieving very high affinity is challenging using the display-based optimization technologies. Here we present an approach that begins with the creation and clonal, quantitative analysis of soluble Fab libraries with complete diversification in adjacent residue pairs encompassing every complementarity-determining region position. This was followed by alternative recombination approaches and high throughput screening to co-optimize large sets of the found improving mutations. We applied this approach to the affinity maturation of the anti-tumor necrosis factor antibody adalimumab and achieved ~500-fold affinity improvement, resulting in femtomolar binding. To our knowledge, this is the first report of the in vitro engineering of a femtomolar affinity antibody against a protein target without display screening. We compare our findings to a previous report that employed extensive mutagenesis and recombination libraries with yeast display screening. The present approach is widely applicable to the most challenging of affinity maturation efforts.     

Femtomolar Fab binding affinities to a protein target by alternative CDR residue co-optimization strategies without phage or cell surface display

In therapeutic or diagnostic antibody discovery, affinity maturation is frequently required to optimize binding properties. In some cases, achieving very high affinity is challenging using the display-based optimization technologies. Here we present an approach that begins with the creation and clonal, quantitative analysis of soluble Fab libraries with complete diversification in adjacent residue pairs encompassing every complementarity-determining region position. This was followed by alternative recombination approaches and high throughput screening to co-optimize large sets of the found improving mutations. We applied this approach to the affinity maturation of the anti-tumor necrosis factor antibody adalimumab and achieved ~500-fold affinity improvement, resulting in femtomolar binding. To our knowledge, this is the first report of the in vitro engineering of a femtomolar affinity antibody against a protein target without display screening. We compare our findings to a previous report that employed extensive mutagenesis and recombination libraries with yeast display screening. The present approach is widely applicable to the most challenging of affinity maturation efforts.     

Spatially addressed combinatorial protein libraries for recombinant antibody discovery and optimization

Antibody discovery typically uses hybridoma- or display-based selection approaches, which lack the advantages of directly screening spatially addressed compound libraries as in small-molecule discovery. Here we apply the latter strategy to antibody discovery, using a library of ～10,000 human germline antibody Fabs created by de novo DNA synthesis and automated protein expression and purification. In multiplexed screening assays, we obtained specific hits against seven of nine antigens. Using sequence-activity relationships and iterative mutagenesis, we optimized the binding affinities of two hits to the low nanomolar range. The matured Fabs showed full and partial antagonism activities in cell-based assays. Thus, protein drug leads can be discovered using surprisingly small libraries of proteins with known sequences, questioning the requirement for billions of members in an antibody discovery library. This methodology also provides sequence, expression and specificity information at the first step of the discovery process, and could enable novel antibody discovery in functional screens.     

Surface display of antibodies

To screen antibody libraries that contain many millions of different clones, a selection system is required with an efficiency comparable to that of the immune system. This can be achieved by displaying antibodies on the surface of microorganisms containing the antibody's gene, analogous to the expression of the IgM antigen receptor on the surface of unactivated B-lymphocytes. Specific clones can then be selected using immobilized antigens. The minor coat protein of filamentous phages, pIII, which initiates the infection of E.coli by binding to their F-pili, and the major coat protein, pVIII, have been used as carriers for displaying antibodies on the phage surface. Recombinant antibodies have also been targeted to the cell surface of bacteria by fusing them with outer membrane components derived from lipoproteins, OmpA and an IgA protease. However, only the pIII system has been routinely used for screening antibody libraries. Here we describe the various antibody surface display systems and the screening of antibody libraries generated from the gene repertoire of lymphocytes and by gene synthesis. Finally, we have made a short comparison of the bacterial production of Fabs versus single chain antibodies (scFv).     

噬菌体抗体库筛选技术

噬菌体展示技术（Ｐｈａｇｅ Ｄｉｓｐｌａｙ Ｔｅｃｈｎｏｌｏｇｙ）为制备高亲和性抗体提供了有力的工具。噬菌体抗体库的筛选是其中关键的环节,为了提高筛选效率,用包被在固体表面的抗原进行筛选的传统方法不断地被改进,如宿主菌直接洗脱和双层膜筛选系统和抗抗体替代抗原筛选系统。将噬菌体感染宿主菌的过程与筛选过程相关联,产生了选择性感染筛选系统。